Cancer Cell Biology

You have full text access to this OnlineOpen article

Signalling responses linked to betulinic acid-induced apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid melanoma irrespective of p53 status

  1. Manuel Rieber*,
  2. Mary Strasberg Rieber

Article first published online: 8 SEP 2005

DOI: 10.1002/ijc.21478

Issue

International Journal of Cancer

International Journal of Cancer

Volume 118, Issue 5, pages 1135–1143, 1 March 2006

Additional Information

How to Cite

Rieber, M. and Rieber, M. S. (2006), Signalling responses linked to betulinic acid-induced apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid melanoma irrespective of p53 status. Int. J. Cancer, 118: 1135–1143. doi: 10.1002/ijc.21478

Author Information

  1. IVIC, Tumor Cell Biology Laboratory, Caracas, Venezuela

*IVIC, Tumor Cell Biology Laboratory, Apartado 21827, Caracas 1020 A, Venezuela

Publication History

  1. Issue published online: 20 DEC 2005
  2. Article first published online: 8 SEP 2005
  3. Manuscript Accepted: 14 JUL 2005
  4. Manuscript Received: 23 FEB 2005

Funded by

  • Conicit. Grant Number: G-97000613

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (697K)

References

  • 1
    Gioeli D, Mandell JW, Petroni GR, Frierson HF,Jr, Weber MJ. Activation of mitogen-associated protein kinase with prostate cancer progression. Cancer Res 1999; 59: 279–84.
  • 2
    Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003; 63: 756–59.
  • 3
    Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5: 810–16.
  • 4
    Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway (Review). Oncogene 2000; 19: 6594–99.
  • 5
    Koo H-M, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Vande Woude GF. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase. Proc Natl Acad Sci USA 2002; 99: 3052–57.
  • 6
    Fukazawa H, Uehara Y. U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways. Cancer Res 2000; 60: 2104–7.
  • 7
    Ge X, Fu YM, Meadows GG. U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells. Cancer Lett 2002; 179: 133–40.
  • 8
    Englaro W, Bertolotto C, Busca R, Brunet A, Pages G, Ortonne JP, Ballotti R. Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation. J Biol Chem 1998; 273: 9966–70.
  • 9
    Tang D, Wu D, Hirao A, Lahti JM, Liu L, Mazza B, Kidd VJ, Mak TW, Ingram AJ. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 2002; 277: 12710–17.
  • 10
    Bedogni B, O'Neill MS, Welford SM, Bouley DM, Giaccia AJ, Denko NC, Powell MB. Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 2004; 64: 2552–60.
  • 11
    Stadheim TA, Xiao H, Eastman A. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells. Cancer Res 2001; 61: 1533–40.
  • 12
    MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000; 275: 38953–4.
  • 13
    Persons DL, Yazlovitskaya EM, Cui W, Pelling JC. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 1999; 5: 1007–14.
  • 14
    Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 2000; 275: 39435–43.
  • 15
    Strasberg Rieber M, Zangemeister-Wittke U, Rieber M. p53 Independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide. Clin Cancer Res 2001; 7: 1446–51.
  • 16
    Rieber M, Strasberg Rieber M. Apoptosis-inducing levels of UV radiation and proteasome inhibitors produce opposite effects on p21(WAF1) in human melanoma cells. Int J Cancer 2000; 86: 462–67.
    Direct Link:
  • 17
    Rieber M, Strasberg Rieber M. N-acetyl cysteine enhances UV-mediated caspase 3 activation, fragmentation of E2F-4, and apoptosis in human C8161 melanoma: inhibition by ectopic bcl-2 expression. Biochem Pharmacol 2003; 65: 1593–1601.
  • 18
    Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CW, Fong HH, Kinghorn AD, Brown DM, Wani MC, Wall ME, et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1995; 1: 1046–51.
  • 19
    Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C, Formelli F. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 2002; 175: 17–25.
  • 20
    Rieber M, Strasberg Rieber M. Induction of p53 without induction of p21WAF1 in betulinic acid-mediated cell death is preferential for human metastatic melanoma. DNA Cell Biol 1998; 17: 399–406.
  • 21
    Wick W, Grimmel C, Wagenknecht B, Dichgans J, Weller M. Betulinic acid-induced apoptosis in glioma cells: a sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J Pharmacol Exp Ther 1999; 289: 1306–12.
  • 22
    Satyamoorthy K, Chehab NH, Waterman MJF, Lien MC, El-Deiry WS, Herlyn M, Halazonetis TD. Aberrant regulation of wild type p53 in radioresistant melanomas. Cell Growth Differ 2000; 11: 467–74.
  • 23
    Darzynkiewicz Z, Bedner E, Li X, Gorczyca W, Melamed MR. Laser scanning cytometry: a new instrumentation with many applications. Exp Cell Res 1999; 249: 1–12.
  • 24
    Strasberg Rieber M, Anzellotti A, Sanchez-Delgado R, Rieber M. Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor. Int J Cancer 2004; 112: 376–84.
    Direct Link:
  • 25
    Mandic A, Viktorsson K, Heiden T, Hansson J, Shoshan MC. The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res 2001; 11: 11–19.
  • 26
    Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273: 18623–32.
  • 27
    Soldatenkov VA, Smulson M. Poly (ADP-ribose) polymerase in DNA damage response pathway: implications for radiation oncology. Int J Cancer 2000; 90: 59–67.
    Direct Link:
  • 28
    Shu CH, Yang WK, Shih YL, Kuo ML, Huang TS. Cell cycle G2/M arrest and activation of cyclin-dependent kinases associated with low-dose paclitaxel-induced sub-G1 apoptosis. Apoptosis 1997; 2: 463–70.
  • 29
    Hoshino R, Tanimura S, Watanabe K, Kataoka T, Kohno M. Blockade of the extracellular signal-regulated kinase pathway induces marked G1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated: up-regulation of p27(Kip1). J Biol Chem 2001; 276: 2686–92.
  • 30
    Gong J, Traganos F, Darzynkiewicz Z. Discrimination of G2 and mitotic cells by flow cytometry based on different expression of cyclins A and B1. Exp Cell Res 1995; 220: 226–31.
  • 31
    Chiariello M, Gomez E, Gutkind JS. Regulation of cyclin-dependent kinase (Cdk) 2 Thr-160 phosphorylation and activity by mitogen-activated protein kinase in late G1 phase. Biochem J 2000; 349: 869–76.
  • 32
    Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-Akt cross-talk. Science 1999; 286: 1738–41.
  • 33
    Huang C, Li J, Ding M, Leonard SS, Wang L, Castranova V, Vallyathan V, Shi X. UV Induces phosphorylation of protein kinase B (Akt) at Ser-473 and Thr-308 in mouse epidermal Cl 41 cells through hydrogen peroxide. J Biol Chem 2001; 276: 40234–40.
  • 34
    Wartenberg M, Frey C, Diedershagen H, Ritgen J, Hescheler J, Sauer H. Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids. Int J Cancer 1998; 75: 855–63.
    Direct Link:
  • 35
    Diarra-Mehrpour M, Arrabal S, Jalil A, Pinson X, Gaudin C, Pietu G, Pitaval A, Ripoche H, Eloit M, Dormont D, Chouaib S. Prion protein prevents human breast carcinoma cell line from tumor necrosis factor α-induced cell death. Cancer Res 2004; 64: 719–27.
  • 36
    Tao GZ, Rott LS, Lowe AW, Omary MB. Hyposmotic stress induces cell growth arrest via proteasome activation and cyclin/cyclin-dependent kinase degradation. J Biol Chem 2002; 277: 19295–303.
  • 37
    Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, Kiyokawa H. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol 1999; 19: 7011–19.
  • 38
    Gingras B, Rodier G, Giasson E, Coulombe P, Chassagne C, Meloche S. Expression of angiotensin type II receptor downregulates Cdk4 synthesis and inhibits cell-cycle progression. Oncogene 2003; 22: 2633–42.
  • 39
    Jørgensen K, Holm R, Mælandsmo GM, Flørenes VA. Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas relationship with clinical outcome. Clin Cancer Res 2003; 9: 5325–31.
  • 40
    Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8: 1168–71.
View Full Article (HTML) Get PDF (697K)